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Platelets play an essential role in hemostasis and atherothrombosis. Owing to their short storage time, there is con-
stant demand for this life-saving blood component. In this study, we report that it is feasible to generate functional 
megakaryocytes and platelets from human embryonic stem cells (hESCs) on a large scale. Differential-interference 
contrast and electron microscopy analyses showed that ultrastructural and morphological features of hESC-derived 
platelets were indistinguishable from those of normal blood platelets. In functional assays, hESC-derived platelets re-
sponded to thrombin stimulation, formed microaggregates, and facilitated clot formation/retraction in vitro. Live cell 
microscopy demonstrated that hESC-platelets formed lamellipodia and filopodia in response to thrombin activation, 
and tethered to each other as observed in normal blood. Using real-time intravital imaging with high-speed video mi-
croscopy, we have also shown that hESC-derived platelets contribute to developing thrombi at sites of laser-induced 
vascular injury in mice, providing the first evidence for in vivo functionality of hESC-derived platelets. These results 
represent an important step toward generating an unlimited supply of platelets for transfusion. Since platelets con-
tain no genetic material, they are ideal candidates for early clinical translation involving human pluripotent stem 
cells.
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Introduction
Platelets play a critical role in stimulating clot forma-
tion and repair of vascular injury. However, because of 
their short life span of only 7-10 days, platelets con-
stantly need to be replaced in order to maintain normal 
levels (150-400 × 10
3/µl) in the blood. Life-threatening 
thrombocytopenia (low platelet counts, generally < 10-
30 × 10
3/µl) can occur in patients for a variety of reasons, 
including chemotherapy, radiation treatment, or organ 
transplant surgery. To circumvent risks associated with 
these conditions, platelet transfusions have become a 
mainstay therapy; yet high demand and limited shelf life 
have created a constant shortage in transfusion supplies 
[1]. The ability to generate HLA-matched platelets in 
vitro would provide significant advantages over currently 
used donor-dependent programs.
Platelet production in vivo is a highly efficient process 
with 2 000-10 000 platelets being produced from each 
megakaryocyte (MK) precursor cell [2, 3]. Signaling 
through thrombopoietin (TPO) and other cytokines in 
the bone marrow (BM), such as interleukin (IL)-3, IL-
6, IL-9, IL-11, bone morphogenetic protein (BMP)-4, 
flt3 ligand (FL), and stem cell factor (SCF) is thought www.cell-research.com | Cell Research
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to facilitate MK maturation and platelet production [4], 
while transcription factors, such as GATA-1 and FOG-
1, are thought to help orchestrate the progressive lineage 
commitment, maturation, and fragmentation of MKs into 
platelets [5-7]. MK maturation involves the acquisition 
of characteristic cell surface markers, such as glycopro-
tein (GP) IIb/IIIa (CD41, also known as integrin αIIbβ3, 
a receptor for fibrinogen), GPIb (CD42b/c), GPIX 
(CD42a), and GPV (CD42d), several rounds of endomi-
tosis, and the accumulation of components necessary for 
platelet biogenesis such as α- and dense-granules, and 
proteins such as von Willebrand factor (vWF) and plate-
let factor 4 (PF4) [8, 9]. Cumulatively, these changes re-
sult in the generation of large polyploid MKs that are 50-
100 microns in diameter, up to 64N in DNA content, and 
primed for thrombopoiesis, i.e., the assembly and release 
of platelets into the blood stream (reviewed by Kosaki 
[10] and Patel et al. [11]). 
Success has been achieved in producing functional 
MKs and platelets from CD34+ hematopoietic cells of 
the BM, cord blood, and peripheral blood (PB) in vitro 
[12, 13]. However, these cells are unable to alleviate the 
ongoing need for donors because of their limited in vitro 
expansion capabilities. In contrast, human embryonic 
stem cells (hESCs) can be propagated in vitro indefinite-
ly, providing a potentially unlimited and donorless source 
of cells for therapeutic purposes. Although two studies 
[14, 15] have provided a proof of principle for in vitro 
production of hESC-derived MKs, only one of them [15] 
extended their studies to include the subsequent produc-
tion of platelets. Despite this pioneering work, the low 
yields of hESC-MKs, labor-intensive methodologies, and 
limited in vitro functionality testing of hESC-platelets 
left critical questions unanswered: (1) can hESC-derived 
MKs and platelets be produced on a clinically relevant 
scale, and (2) are these platelets functional upon transfu-
sion into a living animal?
In this study, we describe an efficient method of gen-
erating functional MKs from hESCs on a large scale 
using hemangioblasts/blast cells (BCs) as intermediates 
[16, 17]. Platelets produced from hESC-derived MKs 
displayed all of the ultrastructural and morphological 
criteria that are typical of blood platelets, and possessed 
characteristic properties of functional platelets, such as 
activation by thrombin, spreading on fibrinogen- and 
vWF-coated surfaces, and formation/retraction of fibrin 
clots. Importantly, fluorescence intravital microscopy 
studies demonstrated that hESC-derived platelets incor-
porated into developing mouse platelet thrombi at sites 
of laser-induced arteriolar wall injury in a manner and 
degree similar to that observed for normal human blood 
platelets. These results provide valuable evidence that 
hESC-derived platelets may be useful for platelet trans-
fusion. 
Results
Large-scale generation of MKs from hESC-derived he-
mangioblasts/BCs
Our previous studies have shown that hemangioblasts/
BC derived from hESCs can efficiently differentiate into 
erythroid cells [18]. Since MKs and erythrocytes share 
a common progenitor during mammalian hematopoi-
esis, we performed a series of experiments to determine 
whether hESC-derived BCs could also be induced to 
differentiate into MKs. BCs harvested from day 6 to day 
8 cultures were first tested for their megakaryopoietic 
potential using a colony-forming unit (CFU)-MK as-
say. Within 10-12 days of plating in Megacult-C media, 
BCs derived from all three tested hESC lines (HuES-3, 
MA01, and MA09) developed CFU-MK colonies and 
stained positive for CD41, with cellular processes resem-
bling proplatelets extending from some of the CD41+ 
cells (Supplementary information, Figure S1). 
To determine which cytokines and growth factors are 
required for BCs to differentiate into MKs, we tested 
Figure 1 Generation and characterization of megakaryocytes (MKs) derived from human embryonic stem cells (hESCs). (A) 
Numbers of CD41a+ cells generated from 8 × 10
4 hemangioblasts/blast cells derived from hESCs after 4-6 day culture in 
Stemline II medium supplemented with TPO (50 ng/ml) or TPO (50 ng/ml) plus SCF (20 ng/ml). ***P < 0.001, n = 4. (B) Aver-
age numbers of CD41a+ cells generated at different days. Blast cells were plated in Stemline II medium supplemented with 
TPO (50 ng/ml), SCF (20 ng/ml) and IL-11 (20 ng/ml), CD41a+ cells from four experiments were analyzed by flow cytometry. (C) 
Flow cytometry analyses of blast cells (day 0 MK culture, left panel), and cells from day 4 MK cultures show the expression 
of CD41a and CD235a (middle panel), and CD41a and CD42b (right panel) antigens. (D) Average size (diameter) of cells 
at the beginning (19.0 ± 4.2 µm, n = 111) and 6 days (25.6 ± 12.5 µm, n = 124) after MK culture. Cells were measured from 
digital images of Giemsa-stained cells. ***P < 0.001. (E) DNA ploidy analysis by flow cytometry of CD41a+ cells. DNA ploidy 
up to 32N was observed in these cells. (F) Giemsa staining of cells from day 6 MK culture. (G) Immunofluorescence of von 
Willebrand factor (vWF, red) and CD41 (green) proteins in cells from day 6 MK culture. vWF is localized in the cytoplasm in a 
punctate pattern, which is typical for MKs. CD41 is expressed on the surface. DAPI (blue) stain shows polynuclei (polyploidy). 
(H) A representative phase contrast image shows the pro-platelet forming MKs in day 4 cultures. Bars = 20 µm.Platelets from hESCs are functional in vitro and in mice
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various cytokines and growth factors in a defined cul-
ture system. Using serum-free Stemline II as the base 
medium, we found that a high concentration (50 ng/ml) 
of TPO was able to support the generation of CD41a+ 
(GPIIb) cells, although with limited efficiency (Figure 
1A). We also observed that most cells died after 6 days 
of culture if TPO was not supplemented. When TPO was 
combined with SCF (20 ng/ml), the number of CD41a+ 
MKs in the differentiation culture significantly increased 
(Figure 1A, P < 0.001, n = 4). However, a combination 
of TPO and SCF with serum or other cytokines such as 
IL-9, BMP-4, FL, and vascular endothelial growth factor 
(VEGF) did not increase MK production (Supplementary 
information, Figure S2). Addition of IL-6, IL-11, and 
basic fibroblast growth factor (bFGF) individually to 
medium containing TPO and SCF was able to increase 
the number of CD41a+ MKs (Supplementary informa-
tion, Figure S2), but none of these effects was statisti-
cally significant (IL-6, P = 0.110; IL-11, P = 0.109; and 
bFGF, P = 0.185, n = 5). Supplementation with all three 
factors (IL-6, IL-11, and bFGF) together did not improve 
the outcome either (data not shown). Despite its modest 
effect, we decided to include IL-11 in our differentiation 
medium, since it was previously reported to enhance 
both the expansion and maturation of MKs [19, 20]. On 
the basis of these results, the MK differentiation medium 
used in our studies consists of Stemline II supplemented 
with TPO (50 ng/ml), SCF (20 ng/ml), and IL-11 (20 ng/
ml), and is referred to as TSI medium. 
Using TSI medium, we were able to achieve a fivefold 
increase in the number of CD41a+ MKs during a period 
of 6 days (Figure 1B). During this period, flow cytom-
etry analysis showed a rapid decrease in CD235a+ (gly-
cophorin A+) cells, coupled with a dramatic increase in 
CD41a+ and CD42b+ (GPIbα) cells. By day 4-6, ~90% 
of the cells expressed CD41a (Figure 1C, Supplementary 
information, Figure S3A), and 80% of the cells were also 
positive for CD42b (Figure 1C). In addition to CD42b, 
CD42a (GPIX) and CD61 (integrin β3 subunit) were also 
expressed on the surface of CD41a+ MKs (Supplemen-
tary information, Figure S3B). After 4-6 days in the TSI 
medium, the average cell size significantly increased as 
well, from 19.0 ± 4.2 µm (mean ± SD, n = 111) in diam-
eter at day 0 to 25.6 ± 12.5 µm (n = 124) at day 6 (Figure 
1D, P < 0.001). By day 6, > 30% of the cells were poly-
ploid with DNA content > 8N (Figure 1E), and > 20% of 
the cells were > 40 µm in diameter (Figure 1F). Collec-
tively, these results suggest that the TSI culture system 
facilitates the production of MKs. Consistent with ob-
servations in the mouse ESC system [21], most MKs in 
our cultures were 2N and 4N, suggesting that they were 
more primitive in nature than what is typically observed 
in vivo. For larger (40-60 µm), more polyploid cells in 
our cultures, Giemsa and immunofluorescence staining 
showed characteristic granular accumulation of vWF 
in the cytoplasm and CD41 staining on the membrane 
(Figure 1F and 1G), confirming that at least some of the 
MKs had reached later stages of maturity. Indeed, ap-
proximately 1-2% of MKs in our TSI cultures contained 
proplatelet-like cellular processes by day 4 (Figure 1H). 
We have tested the ability of three different hESC 
lines (HuES-3, MA01, and MA09) to generate MKs in 
the serum-free and feeder-free TSI conditions. Although 
variable efficiencies were observed from experiment to 
Table 1 Generation of megakaryocytes from human embryonic stem cells (hESC) via hemangioblasts/blast cells
hESC lines   Experiments  Generated CD41+ MK (×10
6)  Fold expansion from hESCs
HuES-3  1  7  30
  2  15  111
  3  114  95
  4  118  104
    
MA09  1  22  113
  2  53  29
  3  191  18
  4  604  53
    
MA01  1  7  65
  2  13  118
CD41+ MK cell counts from cultures were calculated by multiplying total numbers of live cells (trypan blue exclusion) and the percentages of 
CD41a+ cells (flow cytometry analyses). Total fold expansion from hESCs to MKs were calculated by multiplying the fold expansion at each step 
through EB, BC and MK cultures, since not all EB cells or BCs were used for subsequent cultures.Platelets from hESCs are functional in vitro and in mice
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experiment (Table 1), the total expansion of cells from 
hESCs to CD41a+ MKs ranged from 30- to 111-fold for 
HuES-3 cells, 65- to 118-fold for MA01 cells, and 18- to 
113-fold for MA09 cells. Therefore, our results show ap-
proximately 20- to 30-fold greater efficiency in MK pro-
duction than that of a previous report using both serum 
and animal feeder cells [15]. For perspective, starting 
from a single six-well plate of MA09 hESCs (≈ 1.0 × 10
7 
cells), ~ 6 × 10
8 CD41a+ MKs were generated (Table 1). 
With this yield of MKs, ~ 20 standard units of platelets 
(≈ 5.5 × 10
10 platelets/unit) could be produced if in vitro 
thrombopoiesis culture environments were as efficient as 
those in vivo [2, 3].
Generation of functional platelets from hESC-MKs
To determine whether proplatelet-like cellular pro-
cesses observed in our TSI cultures (Figure 1H) reflected 
generation of hESC-derived platelets (hESC-PLTs), we 
examined CD41a/CD42b expression by flow cytom-
etry. Using forward and side scatter profiles of human 
blood platelets to establish proper size gating for hESC-
PLTs (Figure 2A), we found that > 30% of hESC-PLTs 
generated under feeder- and serum-free conditions ex-
pressed CD41a, whereas only ~ 5% of CD41a+ hESC-
PLTs expressed CD42b (Supplementary information, 
Figure S4A). Consistent with recent studies showing 
that the metalloproteinase inhibitor GM6001 signifi-
cantly increased the expression of CD42b on mouse 
ESC-derived platelets [22], we found that addition of 
GM6001 (100 µM) to late stage differentiation cultures 
tripled the percentage of CD41a+ hESC-PLTs that also 
expressed CD42b (Supplementary information, Figure 
Figure 2 Characterization of platelets generated from human embryonic stem cells (hESC-PLTs). (A) The two panels show 
flow cytometry profiles of forward scatter (FSC) and side scatter (SSC; left), and CD41a and CD42b expression (right) on 
blood platelets. Approximately 80% of the gated particles express CD41a (y-axis) and CD42b (x-axis, top right). (B) The two 
panels show a flow cytometry FSC vs SSC profile (left), and CD41a vs CD42b expression (right) on hESC-PLTs. Approxi-
mately 30% of hESC-PLTs derived from OP9 feeder co-culture express both CD41a (y-axis) and CD42b (x-axis, top right). (C) 
Representative microscopic fields of hESC-PLT (top left) and blood platelet (top right) populations examined by differential in-
terference contrast microscopy. Bar = 5 µm. hESc-PLTs are discoid in shape. Thin-section transmission electron microscopy 
of hESC-PLTs (lower left) and blood platelets (lower right). Bar = 1 µm. (D) Expression of P-selectin (PS) and platelet factor 4 
(PF-4) on α-granules of blood platelets and hESC-PLTs. Immunogold electron microscopy of ultrathin cryosections showing 
the localization of P-selectin and PF-4 in resting blood platelets and hESC-PLTs. Bar = 1 µm. www.cell-research.com | Cell Research
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S4B) to ~ 15%, a substantial increase yet still a low total 
yield. Using the limited number of hESC-PLTs generated 
under feeder- and serum-free condition, we performed 
a standard integrin-dependent spreading assay. hESC-
PLTs spread on fibrinogen or vWF-coated surfaces 
(Supplementary information, Figure S5), suggesting 
that they were functional in vitro. Despite the novelty of 
this entirely serum- and feeder-free system, the low ef-
ficiency of functional platelet generation indicates that 
this method needs further optimization. In an attempt 
to facilitate thrombopoiesis and generate greater yields 
of platelets, we amended our differentiation protocol to 
include a stroma cell co-culture step after the initial 4-6 
days of feeder- and serum-free MK production. 
Both OP9 and C3H 10T1/2 mouse stromal cells have 
been shown to support in vitro platelet biogenesis [15, 
21, 22]. To determine whether the supportive effects of 
feeder cells were mediated by secreted factors, we added 
conditioned medium from OP9 or C3H 10T1/2 cells to 
our hESC-MK cultures. Stroma-conditioned medium 
with or without serum had no effect on the generation of 
functional platelets from our hESC-derived MKs. The 
addition of fibrinogen and vWF did not enhance platelet 
production either (data not shown). 
Figure 3 Tubulin and filamentous actin staining in resting blood platelets and hESC-PLTs. Tubulin (green) and filamentous 
actin staining (red) of resting, blood platelets (A) and hESC-PLTs (B). Images are presented as light differential-interference 
contrast, anti-β1-tubulin staining, phalloidin staining, and an overlay. Plot profiles show distance in microns on the x-axis and 
fluorescence intensity on the y-axis. Bar = 5 µm.Platelets from hESCs are functional in vitro and in mice
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To determine whether direct interaction of MKs with 
stroma cells is required for efficient platelet biogenesis, 
hESC-MKs generated from three hESC lines (HuES-3, 
MA01 and MA09) were harvested from day 4-6 cultures 
and plated onto mitotically arrested OP9 cells in α-MEM 
+ 15% fetal bovine serum (FBS), 100 ng/ml TPO, 50 
ng/ml SCF, and 25 U/ml sodium heparin, as previously 
described [15]. Cells were grown in stroma co-culture 
conditions for an additional 4-8 days and the media were 
collected every 2 days to determine the expression of 
CD41a/CD42b by flow cytometry. In contrast to hESC-
PLTs generated under stroma-free conditions, the major-
ity of CD41a+ hESC-PLTs also expressed CD42b (Figure 
2B and Supplementary information, Figure S6) and 
GM6001 did not significant increase the CD41a/CD42b 
double-positive population (data not shown).
These hESC-PLTs exhibit each of the characteristic 
features of blood platelets as demonstrated by differ-
ential-interference contrast microscopy. They appeared 
disc-shaped and measured approximately 2-3 µm in di-
ameter and displayed a key feature of resting platelets – 
a prominent, circumferential band of microtubules with a 
diameter similar to that observed in blood platelets (Figure 
2C, upper panels, Figure 3). Examination of hESC-PLTs 
by thin-section electron microscopy demonstrated ul-
trastructural similarities between hESC-PLTs and blood 
platelets. hESC-PLTs displayed a smooth contour and 
contained a normal distribution of the open canalicular 
system as well as α- and dense granules and other or-
ganelles, which are indistinguishable from those isolated 
from plasma (Figure 2C, lower panels). In addition, 
hESC-PLTs showed strong expression of P-selectin in the 
α-granules. Immunogold electron microscopy revealed 
that expression levels were similar to that observed in 
blood platelets, and P-selectin was primarily localized to 
the membranes of α-granules (Figure 2D, upper panels). 
PF-4 was also localized to α-granules, and gold density 
was similar to that observed in blood platelets (Figure 
2D, lower panels). In summary, hESC-PLTs displayed all 
of the ultrastructural and morphological criteria that dis-
tinguish blood platelets. On average (calculated from six 
different wells), 6.7 ± 0.4 hESC-PLTs were generated per 
hESC-MK, the efficiency of which is comparable with 
that previously reported for in vitro platelet production 
from hESC-MKs [15], but is still much less efficient than 
that observed in vivo [2, 3], suggesting the method needs 
to be further optimized. We, therefore, used hESC-PLTs 
generated with OP9 co-culture to perform a variety of 
functional assays. 
We first tested the response of these hESC-PLTs to 
agonist stimulation. Similar to hESC-PLTs generated un-
der feeder-free TSI conditions (Supplementary informa-
tion, Figure S5) and normal blood platelets (Figure 4A), 
hESC-PLTs produced in OP9 co-cultures adhered to and 
spread on fibrinogen- (Figure 4B) or vWF-coated sur-
faces (data not shown). An RGDS peptide, which blocks 
fibrinogen binding to platelet GP IIb/IIIa (αIIbβ3 integ-
rin), abolished the adhesion and spreading of both human 
blood platelets and hESC-PLTs (Figure 4A and 4B). Live 
cell microscopy revealed spreading, lamellipodia and 
filopodia formation, and membrane ruffling of hESC-
PLTs; they also spread out and tethered to each other 
within 10 min after thrombin activation, mimicking the 
early stage of aggregation, which are typically observed 
in blood platelets in response to thrombin activation 
(Figure 4C and Supplementary information, Video S1). 
In addition, hESC-PLTs adhered to and formed small ag-
gregates on surfaces coated with fibrillar collagen type 
I under static conditions and treatment with a blocking 
anti-α2β1 integrin antibody inhibited this adhesion (Sup-
plementary information, Figure S7). 
Consistent with previous reports showing a size dis-
crepancy between in vitro generated murine and human 
platelets as compared with their PB counterparts [15, 21-
24], we also found that hESC-PLTs were larger and more 
heterogeneous than human blood platelets in spreading 
Figure 4 Functional characterization of hESC-PLTs in vitro. (A) Human blood platelets and (B) hESC-PLTs spread on fibrino-
gen surface: microtiter chamber slides were coated with 100 µg/ml fibrinogen and human blood platelets treated with vehicle 
(CON, top left), 1 mM RGDS peptide (+RGDS, top right), 20 µM ADP (+ADP, bottom left) or 1 U/ml of thrombin (+TH, bot-
tom right), were plated and incubated for 90 min. Adherent platelets were stained with Alexa Fluor 568 phalloidin (red), FITC 
conjugated anti-human CD41a (green) antibodies, and DAPI (blue), and photographed under a fluorescence microscope. 
Bar = 10 µm. (C) Representative images are shown at four time points after thrombin stimulation. Arrows indicate hESC-PLTs 
spreading, lamellipodia and filopodia formation, membrane ruffling, and some of hESC-PLTs were tethered together. (D) The 
left two panels are representative dot plots for blood platelets binding to FITC-conjugated PAC-1 antibody in the absence 
(left) and presence (right) of thrombin (1 U/ml). A dramatic increase of FITC-conjugated PAC-1 antibody binding (right shift) is 
observed for thrombin-treated human platelets as compared with resting controls. The right two panels are representative dot 
plots for hESC-PLTs binding to FITC-conjugated PAC-1 antibody in the absence (left) and presence (right) of thrombin (1 U/
ml). A moderate increase in FITC-conjugated PAC-1 antibody binding (right shift) is observed for thrombin treated hESC-PLTs 
as compared with resting controls. Platelets from hESCs are functional in vitro and in mice
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assays. After adherence to bovine serum albumin (BSA)-
coated surfaces (Supplementary information, Figure S8), 
hESC-PLTs had an average diameter of 3.41 ± 1.11 µm 
(1.82 to 5.76 µm), while blood platelets had an aver-
age diameter of 2.76 ± 0.52 µm (1.77 to 4.06 µm). Af-
ter spreading on fibrinogen surfaces, hESC-PLTs had a 
diameter of 14.32 ± 4.49 µm (7.37 – 25.79 µm), while 
blood platelets had a diameter of 9.08 ± 1.85 µm (6.32 – 
13.16 µm). Many factors may contribute to this disparity, 
one of them may be that hESC-PLTs were produced un-
der static conditions, while normal human blood platelets 
were generated under high shear flow force in vivo [25]. 
Despite this size difference, these results suggest that 
hESC-PLTs are capable of spreading on a variety of sub-
strate-coated surfaces (collagen, fibrinogen, and vWF) 
and that their adherence occurs through known receptor-
mediated mechanisms (e.g., α2β1 integrin-dependent 
binding to collagen type I, and αIIbβ3 integrin-dependent 
binding to fibrinogen). 
On activation, platelet αIIbβ3 integrin binding to sub-
strates, such as fibrinogen or vWF, stimulates thrombus 
formation at the site of vascular injury (reviewed by 
Coller and Shattil [26]). To determine the extent of func-
tional αIIbβ3 integrin expression that occurs on plate-
let activation, we performed a binding assay using the 
PAC-1 monoclonal antibody, a fibrinogen mimetic that 
only binds to the activated conformation of the αIIbβ3 
integrin. In response to thrombin treatment, hESC-PLTs 
generated from OP9 co-cultured HuES3-MKs showed 
approximately a fivefold increase in PAC-1 binding as 
compared with resting controls (Figure 4D, right two 
panels). In addition to HuES3 cells, hESC-PLTs derived 
Figure 5 Functional characterization of hESC-PLTs in vitro. (A and B) Aggregation assay: 3 × 10
5 PKH67 (green) labeled 
blood platelets (A) or 3 × 10
5 PKH67 labeled hESC-PLTs (B) were mixed with unlabeled blood platelets (6 × 10
7) and throm-
bin (0.5 U/ml), then stirred to trigger platelet aggregation. Phase contrast (left) and fluorescent images (center) were merged 
(right) to demonstrate the participation of labeled blood platelets or hESC-PLTs into micro-aggregates. In control experiments, 
RGDS peptide was added before thrombin stimulation and no aggregation was observed. (C and D) Clot formation and re-
traction: (C) platelet-depleted human plasma was added with (+PLTs) or without (−PLTs) hESC-PLTs (1.5 × 10
7/ml), and (D) 
platelet-depleted human plasma was added with human blood platelets (1.5 × 10
7/ml). Thrombin (2 U/ml) and CaCl2 (10 mM) 
were then added to the suspensions to induce clot formation/retraction (C and D, left panels). Clot cryo-sections (C and D, 
right panels) were stained with anti-human CD41 (red) and anti-human fibrin (green) antibodies. Images were taken under a 
fluorescence microscope. No clot formation/retraction was observed without addition of hESC-PLTs (C, left panel −PLTs). Bar 
= 50 µm.www.cell-research.com | Cell Research
Shi-Jiang Lu et al.
539
npg
Figure 6 Incorporation of hESC-PLTs into developing mouse platelet thrombi at sites of laser-induced arteriolar injury in liv-
ing mice. Calcein AM-labeled human blood platelets or hESC-derived platelets, 50-100 µl (5-10 × 10
5 platelets), were infused 
through a femoral artery cannulus immediately after laser-induced vascular injury. The developing mouse platelet thrombus 
was monitored by infusion of Dylight 649-labeled anti-mouse CD42 (0.05 µg/g body weight). After generation of two to three 
thrombi, the labeled platelets were pretreated with ReoPro, 20 µg for 2 × 10
6 human platelets in 200 µl, and infused after new 
vessel injury in the same mouse. Another two to three thrombi were generated to examine incorporation of ReoPro-treated 
platelets. Data were collected for 3 min following vessel injury. (A) Representative fluorescence images are shown at three 
time points (0, 1/2 Tmax, and Tmax) following vascular injury. Magnified images of the area within the white rectangle are shown 
at the bottom. Bar = 10 µm. (B and C) The number of labeled human platelets circulating into the microvessel (B) and incor-
porating into the developing mouse platelet thrombus at the site of vessel injury (C) was counted over 3 min after vascular 
injury. Data represent mean ± S.E.M. (n = 5-8 thrombi in three mice). *P < 0.05 and **P < 0.01 vs a control, Student’s t-test.
from two clinical grade hESC lines, MA01 and MA09, 
also expressed CD41a and CD42b antigens (Supple-
mentary information, Figure S6), and bound PAC-1 in 
response to thrombin stimulation (Supplementary infor-
mation, Figure S9). Consistent with a previous report 
[15], PAC-1 binding in response to thrombin was weaker 
for hESC-PLTs than for blood platelets. In response to 
thrombin stimulation, PAC-1 binding to blood platelets 
increased from 3.2% to 80.3% (Figure 4D, left two pan-
els), while it increased to a lesser degree for hESC-PLTs 
(4.7% to 24.8%, 1.8% to 18.0%, and 2.0% to 28.6% for 
hESC-PLTs derived from HuES-3, MA01, and MA09 
cells, respectively; Figure 4D, right panels and Supple-
mentary information, Figure S9). The decreased binding 
capacity of hESC-PLTs may result from multiple factors, 
one of them is the heterogeneous size distribution of Platelets from hESCs are functional in vitro and in mice
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hESC-PLTs as described above. We also observed that 
> 80% of blood-PLTs were CD41+/CD42+, while only 
40% of hESC-PLTs were CD41+/CD42+ (Figure 2A and 
2B). Particles other than CD41+/CD42+ hESC-PLTs and 
aged hESC-PLTs (collected on days 6 or 7 after plating 
MKs on OP9 stromal cells) may also contribute to the 
decreased binding capacity. 
hESC-PLTs participate in microaggregate formation and 
clot formation/retraction 
To examine agonist-induced aggregation, hESC-PLTs 
generated by co-culture with OP9 cells were labeled with 
green fluorescent dye, mixed with human blood platelets, 
and stimulated with thrombin. In response to thrombin 
stimulation under stirring conditions, the labeled hESC-
PLTs formed microaggregates together with human 
blood platelets as confirmed by phase-contrast and fluo-
rescence microscopy. The distribution of hESC-PLTs in 
these microaggregates was similar to that observed for 
the same number of fluorescently labeled human blood 
platelets (Figure 5A and 5B). These results demonstrate 
that hESC-PLTs together with human blood platelets can 
form aggregates in response to the appropriate stimula-
tion.
Another important function of activated platelets is 
to retract fibrin clots [27, 28]. We found that addition of 
hESC-PLTs to platelet-depleted plasma led to clot forma-
tion and retraction in < 30 min following thrombin stim-
ulation (Figure 5C, left panel +PLTs), whereas no clots 
formed in plain plasma in the absence of platelets even 
when stimulated with thrombin for > 1 h (Figure 5C, left 
panel –PLTs). Similar to clot sections formed with hu-
man blood platelets (Figure 5D), immunofluorescence 
microscopy of cryo-sectioned clots derived from hESC-
PLTs showed mesh-like networks formed by both fibrin 
and platelets (CD41a staining, Figure 5C, right panel). 
These results indicate that hESC-PLTs possess the ability 
to form compact platelet plugs and to promote fibrin clot 
formation and retraction.
hESC-PLTs are incorporated into the developing platelet 
thrombus at the site of laser-induced arteriolar injury in 
living mice
To determine whether hESC-PLTs can contribute to 
clot formation in vivo, we used a laser-induced vascular 
injury mouse model coupled with fluorescence intravital 
microscopy. To monitor mouse platelet thrombus forma-
tion, Dylight 649-labeled anti-mouse CD42 antibody was 
infused into wild-type male mice (C57BL/6, 6-8 week 
old, n = 3) before micropoint laser ablation in the cre-
master muscle arteriole. To account for natural variabil-
ity in thrombus size, 5-8 ablations were made per mouse. 
Since anti-CD42 specifically binds to platelets, the size 
of the mouse platelet thrombus that forms after vessel 
injury can be measured by the fluorescence intensity of 
Dylight 649. Consistent with a previous report [29], the 
median integrated fluorescence signal indicated platelet 
accumulation began 5-20 s after vascular injury, while 
half maximal accumulation occurred 49-70 s (1/2 Tmax) 
and peak accumulation occurred 70-95 s (Tmax) after vas-
cular injury (Supplementary information, Figure S10). 
When 5-10 × 10
5 human peripheral platelets labeled with 
calcein AM (green) were infused after injury, 41.0 ± 2.8 
circulating platelets were detected in the microcirculation 
near the site of laser-induced vascular injury (Figure 6A 
and 6B). Among them, 6.4 ± 1.1 platelets incorporated 
into the developing mouse platelet thrombus within a 
Tmax of 73 s (Figure 6A and 6C, Supplementary informa-
tion, Video S2). 
To confirm that the incorporation of human blood 
platelets into the developing thrombus is mediated by 
αIIbβ3 integrin, human platelets were pretreated with 
ReoPro, a Fab fragment of a human-murine chimeric 
monoclonal antibody that specifically binds to αIIbβ3 
integrin on human platelets and inhibits its function [30], 
before infusion. While the number of circulating platelets 
was not significantly affected by treatment with ReoPro 
(32.4 ± 4.4, Figure 6B), the number of human platelets 
binding to the developing mouse platelet thrombus was 
significantly reduced to 1.6 ± 0.5 by the time the Tmax 
was reached (67 s; Figure 6A and 6C, Supplementary 
information, Video S3, P < 0.01). ReoPro did not affect 
mouse platelet thrombus formation at the site of vascular 
injury. These results indicate that human platelets can 
bind to a mouse platelet thrombus developing at the site 
of vascular injury and that this binding is mediated by 
αIIbβ3 integrin. 
When 5-10 × 10
5 hESC-PLTs labeled with calcein 
AM (green) were infused after vascular injury, 34.8 ± 1.7 
circulating platelets were detected in the microcircula-
tion (Figure 6A and 6B). Among them, 4.3 ± 0.7 plate-
lets bound to the growing mouse platelet thrombus that 
formed at the site of vascular injury within the Tmax of 72 
s (Figure 6A and 6C, Supplementary information, Video 
S4). The difference in number of human blood platelets 
vs hESC-PLTs incorporating into the developing mouse 
platelet thrombus was not statistically significant (P = 
0.28). Similar to blood platelets, pretreatment of hESC-
PLTs with ReoPro also significantly reduced the number 
of platelets that incorporated into the mouse platelet 
thrombus to 1.2 ± 0.4 by the time the Tmax (99 s) was 
reached (Figure 6A and 6C, Supplementary information, 
Video S5, P < 0.05). These results provide the first evi-
dence that hESC-PLTs, such as blood platelets, are func-www.cell-research.com | Cell Research
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tional at the site of vascular injury in vivo.
Discussion
High clinical demand for donated platelets has stimu-
lated interest in generating renewable sources of trans-
fusable platelets. Although hESCs could potentially 
mitigate the need for platelet donation entirely, to do so 
will require clinically adaptable methods for the in vitro 
differentiation of hESCs into MKs, and their maturation 
and fragmentation to produce high yields of functional 
platelets. In this study, we demonstrate an efficient 
method for the differentiation of hESCs into MKs, and 
that the platelets subsequently generated are functionally 
similar to normal blood platelets in vitro as well as in liv-
ing animals. This system is both amenable to large-scale 
production efforts and provides the first known evidence 
for the in vivo functionality of hESC-derived platelets. 
Two previous studies [14, 15] have demonstrated 
the feasibility of the first step (generation of MKs from 
hESCs), but also highlight critical issues that need to be 
resolved. In both studies, animal stromal cells and animal 
serum were required throughout the MK generation pe-
riod, making these methods difficult to adapt for clinical 
production. In addition, the yield of MKs in these sys-
tems is low. Gaur et al. [14] reported the generation of 
less than one (0.1 to 0.4) MK from each hESC. Although 
Takayama et al. [15] improved on this yield (generating 
two to five MKs per hESC), the use of handpicking hES-
sacs significantly hinders the ability to translate this to a 
clinically relevant scale. The present system, which uses 
hemangioblast/BC intermediates, is exponentially more 
efficient in generating CD41a+ MKs than previous meth-
ods, and can be carried out under defined serum- and 
animal feeder-free conditions. 
Although the maturation and fragmentation of MKs in 
vivo leads to the generation and release of platelets, this 
thrombopoietic process has proven extremely difficult to 
recapitulate in vitro. On generating MKs from hESCs, 
Takayama et al. [15] have been the only group to report 
the subsequent production of platelets from hESC-de-
rived MKs. By continuing to grow their MKs on animal 
feeder cells, platelets were subsequently produced and 
shown to be functional using in vitro methods. Although 
we also found that efficient platelet generation from MKs 
required conventional stroma co-culture, importantly, we 
provide the first in vivo evidence for human hESC-PLTs 
functionality. In vitro, our hESC-PLTs showed the abil-
ity to adhere and spread on fibrinogen-, vWF-, and type 
I collagen-coated surfaces (Figure 4B and 4C, Supple-
mentary information, Figure S7 and Video S1) and to 
aggregate when stimulated with physiological agonists 
(Figure 5B). Moreover, our results show that hESC-PLTs 
can retract fibrin clots through a predicted integrin-medi-
ated retractile motion (Figure 5C). Since clot retraction 
promotes wound healing, and thus long-term vascular 
health, it was important to verify this critical feature of 
platelet functionality.
Thrombus formation in vivo is a rapid and highly 
dynamic process involving a large number of signal-
ing pathways, enzymatic cascades, and the interplay of 
various protein components. In the past decade, several 
experimental models have been established to investigate 
thrombus formation in mice, including the laser-injury 
thrombosis model (see reviews by Day et al. [31], Sachs 
and Nieswandt [32], and Yu et al. [33]). By inducing 
natural platelet thrombus formation at the site of vascular 
injury in as little as 5-20 s, this system enabled us to 
monitor the real-time incorporation of human platelets or 
hESC-PLTs into a newly forming thrombus before they 
could be cleared from the microcirculation. We found 
that hESC-PLTs, such as human blood platelets, incor-
porated into the developing mouse platelet thrombus 
through an αIIbβ3 integrin-dependent mechanism. The 
number of hESC-PLTs interacting with the mouse throm-
bus was slightly lower than that of human blood platelets 
(Figure 6C). While this difference was not statistically 
significant, we hypothesize that reduced PAC-1 binding 
of activated hESC-PLTs compared with that of activated 
human blood platelets (Figure 4D and Supplementary 
information, Figure S9) may be partially responsible. 
One other contributing factor may be the larger and more 
heterogeneous size of hESC-PLTs than human blood 
platelets. While normal human blood platelets are gener-
ated under high shear flow force in vivo [25], platelets 
collected from in vitro cultures are produced under static 
conditions, and this difference in their biogenesis could 
contribute to subtleties in feature and function. Further-
more, the aged hESC-PLTs collected on days 6 or 7 after 
plating MKs on OP9 stromal cells may be another con-
tributing factor.
In conclusion, the study described here represents 
an important step in developing a renewable, donorless 
source of transfusable platelets. In addition to reducing 
dependence on animal serum and stroma, thus making 
the process more amenable to clinical translation, we 
have provided the first in vivo evidence of hESC-PLT 
functionality. Megakaryopoiesis and thrombopoiesis are 
highly complex processes, with sophisticated reorganiza-
tion of membranes and microtubules as well as precise 
distributions of granules and organelles [25]. The ability 
to generate MKs under serum- and feeder-free conditions 
and to examine platelet functionality in vivo should aid in 
the screening of factors to further optimize in vitro cul-Platelets from hESCs are functional in vitro and in mice
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ture methods. Importantly, by using induced pluripotent 
stem cells [34-37], it may be possible to adapt these dif-
ferentiation protocols to produce patient-specific platelets 
for transfusion-dependent patients who develop platelet 
alloimmunity. 
Materials and Methods
Generation of MKs and platelets from hESCs via hemangio-
blasts/BCs
Hemangioblast/BC generation from hESC lines (HuES-3, 
MA01 and MA09) was performed as previously reported [16, 17]. 
IL-6, IL-9, IL-11, basic FGF, VEGF, TPO, and SCF were obtained 
from Peprotech, BMP-4 was obtained from Stemgent. BCs from 
day 6 to 8 cultures were purified and plated (1 to 5 × 10
5/ml) in 
“TSI medium” which consisted of Stemline II (Sigma-Aldrich, 
St Louis, MO, USA) supplemented with 50 ng/ml TPO, 20 ng/
ml SCF, and 20 ng/ml IL-11 (all from Peprotech) to induce BC 
differentiation toward MKs. Half of the MK culture medium was 
replaced with fresh TSI medium every 2 or 3 days. Platelet gen-
eration from MKs was performed under either stroma feeder-free 
or stroma feeder co-culture conditions, as indicated. For feeder-
free platelet generation, MKs from day 4 to 6 cultures were simply 
maintained in TSI medium for an additional 4-8 days, whereupon 
platelets were collected intermittently for analysis. In some experi-
ments, GM6001 (100 µM) was added to late stage differentiation 
cultures. For feeder co-culture experiments, OP9 or C3H 10T1/2 
stromal cells were maintained in OP9 culture medium (α-MEM 
with 15% Hyclone fetal bovine serum). Confluent OP9 or C3H 
10T1/2 cells were treated with 100 ng/ml mitomycin-C the day 
before co-culture, gently washed twice with PBS and allowed to 
recover overnight in OP9 culture medium. MKs from day 4 to 6 
cultures were collected and replated onto mitotically inactivated 
OP9 or C3H 10T1/2 stromal cells in OP9 culture medium plus 100 
ng/ml TPO, 50 ng/mlSCF, and 25 U/ml sodium heparin, as previ-
ously described [15]. Platelets were intermittently collected 4 to 8 
days later for various analyses.
Hematopoietic colony formation assays
Megacult-C Kit (Stem Cell Technology, Canada) was used for 
CFU-MK colony formation assays. After 10 day of plating, CFU-
MK cultures were dehydrated, fixed, and stained with anti-CD41 
antibody as suggested by the manufacturer. CFU-MK colonies 
were scored according to the standards provided in the Megacult-C 
protocol.
Flow cytometry analysis
Cells from blast cultures or MK cultures were monitored rou-
tinely by flow cytometry on a FACSCalibur (Becton Dickinson) 
or Accuri C6 Cytometer (Accuri Cytometers). Fluorochrome-
conjugated antibodies for lineage markers, CD41a, CD42a, 
CD42b, and CD235a (BD Biosciences) were used to characterize 
MK and erythroid lineages. Antibodies were freshly prepared 
(1:100 dilution for CD42a and CD42b antibodies; 1:250 dilution 
for CD41a antibody; 1:2 000 for CD235a antibody) in PBS buffer 
with 5% FBS. Typically 1 to 2 × 10
5 cells were used for antibody 
labeling. Cells were stained in a 100 µl antibody cocktail for 1 h 
on ice, then washed twice with buffer, and resuspended in 250 µl 
buffer supplemented with 1 µg/ml propidium iodide. To detect the 
expression level of HLA-ABC, platelets were incubated with a 
fluorescein isothiocyanate (FITC)-conjugated anti-human HLA-
ABC antibody or FITC-conjugated mouse immunoglobulin G (IgG) 
as a control. The samples were then processed on a FACSCalibur 
and data was analyzed using Cellquest Pro (BD Biosciences) or 
Flowjo (Tree Star) software. 
DNA content analysis
For polyploidy analysis, cells from day 4-6 MK cultures were 
fixed in 70% ethanol for 2 h. Cells were then washed once in PBS 
buffer before staining with 20 µg/ml propidum iodide (Sigma-
Aldrich), 20 µg/ml RNase A (Sigma-Aldrich) in PBS buffer over-
night at 4 °C. Cellular DNA content was analyzed on an Accuri C6 
flow cytometer.
Cytospin preparation, Giemsa staining, and immunofluores-
cence
Cells (1 to 2 × 10
4) from either blast cultures or MK cultures 
were cytospun onto polylysine-coated slides (Wessco). Slides 
were either used for Wright-Giemsa (Sigma-Aldrich) staining or 
immunofluoroscence. All incubations were performed at room 
temperature. Cells were blocked with animal-free blocker (Vector 
Laboratories) for 30 min, incubated with primary antibodies for 1 
h, and then washed three times with PBS. For MK identification, 
primary antibodies include anti-CD41 (1:100; Dako cytomation, 
Carpinteria, CA, USA) and anti-vWF (1:200, Dako). Cells were 
incubated with secondary antibodies (1:200 each) for 30 min 
in the dark, and washed again three times in PBS. DAPI (1 µg/
ml) in PBS was used to stain nuclei for 5 min followed by three 
more PBS washes. Slides were then mounted and examined under 
Olympus BX51 fluorescence microscope (MVI, Avon, MA, USA). 
Fluorescent images were captured using a QICAM Fast camera 
(QImaging, Surrey, BC, Canada) and analyzed with Q Capture Pro 
version 5.1 software (Media Cybernetics, Bethesda, MD, USA). 
Phase contrast live cell images were captured using a Nikon mi-
croscope, PAXCAM digital camera and PAX-it software.
Preparation of human blood platelets and hESC-derived 
platelets
Human platelets were isolated as previously described [38]. 
Briefly, human platelet-rich plasma was prepared by centrifuga-
tion of sodium citrate-treated human blood at 200× g for 20 min. 
The supernatant was collected and centrifuged at 700× g for 10 
min in the presence of 0.5 µM PGE1 and 10% sodium citrate buf-
fer. The pellet was resuspended with HEPES-Tyrode buffer (12 
mM NaHCO3, 138 mM NaCl, 5.5 mM Glucose, 2.9 mM KCl, 
0.42 mM NaHPO4, 10 mM HEPES, 1 mM CaCl2, 1 mM MgCl2) 
containing 0.15 µM PGE1, and centrifuged at 800× g for 5 min. 
The pellet was resuspended in RPMI1640 containing 0.1% fatty 
acid-free bovine serum albumin, 2 mM CaCl2, and 1 mM MgCl2. 
Final suspensions of washed platelets were adjusted to 1 × 10
7 
platelets/ml. Approval to obtain blood samples was obtained from 
the University of Illinois-Chicago review board. Informed consent 
was provided according to the Declaration of Helsinki. In some 
experiments, human blood samples were also obtained from a 
commercial source (AllCells, Emeryville, CA, USA). For hESC-
PLTs, culture media containing hESC-PLTs were gently collected 
with apyrase (1 U/ml) and EDTA (5 mM; Sigma-Aldrich) being www.cell-research.com | Cell Research
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added to prevent platelet activation. hESC-PLTs were enriched and 
washed as described above. Washed blood platelets and hESC-
PLTs were incubated at 37 °C for 0.5-2 h before functional assays 
were performed.
Differential interference contrast and electron microscopy 
analyses
To study cell shape, hESC-PLTs were fixed with 1% glu-
taraldehyde in platelet buffer for 20 min, moved to a coverslip 
chamber, and viewed with a 63× differential interference contrast 
objective. Images were obtained using a cooled CCD camera with 
Metamorph software (Universal Imaging). Anti-tubulin immuno-
fluorescence microscopy was performed as described previously 
[39]. Images were analyzed using the Metamorph image analysis 
software (Molecular Devices, Sunnyvale, CA, USA). Plot pro-
files were generated using ImageJ (NIH, http://rsb.info.nih.gov/
ij/). Thin-section electron microscopy was carried out as previ-
ously described [40]. Anti-P-selectin and anti-PF-4 immunogold 
electron microscopy was carried out as described previously [41]. 
Live cell video microscopy of platelets undergoing activation was 
performed using previously described methods [42]. Images of 
spreading platelets were captured every 5 s for 10 min.
Platelet spreading on various substrates
Spreading and adhesion of blood platelets and hESC-PLTs on 
immobilized surfaces of fibrinogen, vWF, type I collagen, and 
BSA were performed as reported [21, 43]. Chamber slides with 
microtiter wells (Nalgen Nunc, Rochester, NY, USA) or cover-
slips were coated with 100 µg/ml fibrinogen or vWF (30 µg/ml; 
Sigma-Aldrich), acid-soluble fibrillar type I collagen (20 µg/ml, 
Millipore) or 1% fatty acid-free BSA (Sigma-Aldrich) in 0.1 M 
NaHCO3 (pH 8.3) at 4 °C overnight. Washed human blood plate-
lets or hESC-PLTs (1 × 10
7/ml) were allowed to adhere and spread 
on protein-coated wells at 37 °C for 90 min. In some experiments, 
platelets were preincubated with an αIIbβ3 integrin antagonist 
(RGDS peptide) for 5 min before loading. In other experiments, 
platelets were mixed with ADP (20 µM) or thrombin (1 U/ml; 
Sigma-Aldrich), or were pretreated with 20 µg/ml of isotype 
control mouse IgG1 or a blocking anti-α2β1 antibody (BHA2.1, 
Millipore) for collagen-coated surfaces, and immediately loaded 
onto fibrinogen-, vWF-, or collagen-coated wells, as indicated. 
After washing with PBS buffer, cells were fixed, permeabilized, 
and stained with Alexa Fluor 568 phalloidin (Molecular Probes, 
Eugene, OR, USA), FITC conjugated anti-human CD41a antibody 
(Dako cytomation) and DAPI. Adherent platelets were viewed 
with
 an Olympus BX51 fluorescence microscope using a PlanApo 
lens at 100×/1.40 oil objective, or using a Nikon microscope (E400) 
equipped with a 100×/1.3 NA oil objective. Images were acquired 
using a QICAM Fast
 camera and processed with Q Capture ver-
sion 5.1 software, or using a CoolSNAP camera (ES2, 1 392 × 1 
040 imaging pixels, Photometrics, Tucson, AZ, USA), and NIS 
Element software (Advanced, v3.1).
Formation of platelet microaggregates
Washed human blood platelets and hESC-PLTs were resuspend-
ed in modified Tyrode buffer and labeled with a PKH67 Green 
Fluorescent Cell Linker (10 µM, Sigma-Aldrich). Human blood 
platelets (6 × 10
7) were mixed with fluorescence-labeled human 
blood platelets (3 × 10
5) or hESC-PLTs (3 × 10
5) in a 450 µl cu-
vette (Chronolog, Havertown, PA, USA), treated with thrombin (0.5 
U/ml) and stirred at 1 200 r.p.m. at 37 °C to trigger platelet aggre-
gation. In control experiments, platelets were preincubated with 
RGDS peptide at 37 °C for 5 min before the addition of thrombin, 
and then aggregation assays were performed as above. Platelet 
microaggregates in 50 µl buffer were spread onto glass slides and 
visualized under an Olympus BX51 fluorescence microscope. 
PAC-1 binding assay
Human blood platelets or hESC-PLTs with or without thrombin 
stimulation (1 U/ml, incubation at room temperature for 20 min) 
were stained with APC-conjugated CD41a, PE-conjugated CD42b, 
and FITC-conjugated PAC-1 antibodies in modified Tyrode’s 
buffer. The samples were then analyzed using a FACSCalibur. 
Forward vs side scatter gating was determined using human blood 
platelets as controls. Flow cytometry data was analyzed using 
Cellquest Pro or Flowjo software.
Clot formation and retraction
Human blood platelets or hESC-PLTs (approximately 1.5 × 
10
7/ml) were resuspended in 50 µl platelet-depleted plasma in 
a siliconized glass tubes (Kimble Chase, Vineland, NJ, USA). 
Thrombin (2 U/ml) was added to the cells to induce clot formation 
and retraction. The clots were allowed to retract at 37 °C for 1 h 
and photographed. Clots were embedded in Tissue-Tek OCT com-
pound and Tissue-Tek Cryomolds (Sakura Finetek, Torrance, CA, 
USA), and then frozen in dry ice. 10 µm clot sections were made 
using a cryostat microtome Microm HM 560 (Thermo Scientific, 
Kalamazoo, MI, USA). Slides were fixed with methanol/acetone 
(1:3) for 30 min, washed with PBS, and permeabilized with 
0.1% Triton X-100, 0.1 M Tris, 10 mM EGTA, 0.15 NaCl, 5 mM 
MgCl2, and 1% BSA, pH 7.5. After blocking with 5% BSA and 
washing with PBS, sections were immunostained with rabbit anti-
human integrin αIIb (clone H-160) and mouse anti-human fibrin 
(clone UC45) antibodies (Santa Cruz Biotech, Santa Cruz, CA, 
USA). Sections were then incubated for 1 h in a 1:200 dilution of 
rhodamine-anti-rabbit IgG and FITC-anti-mouse IgM (Jackson 
ImmunoResearch Laboratory, Bar Harbor, ME, USA). Images 
were taken as described above. 
Intravital microscopy
Male wild-type mice (C57BL/6, 6-8 week old) were purchased 
from the Jackson ImmunoResearch Laboratory. The University of 
Illinois Institutional Animal Care and Use Committee approved all 
animal care and experimental procedures. Wide field, multichan-
nel intravital microscopy of the cremaster muscle microcirculation 
was performed as previously described [29, 44]. Male mice were 
anesthetized by an intraperitoneal injection of ketamine (125 mg/
kg, Bedford Laboratories, Bedford, OH, USA) and xylazine (25 
mg/kg, Akorn, Decatur, IL, USA). A tracheal tube was inserted and 
the mouse was placed on a thermo-controlled blanket (37 °C). To 
maintain anesthesia, 50 µl of the ketamine and xylazine solution 
was administered every 30 min through a cannulus placed in the 
jugular vein. An additional cannulus, filled with saline containing 
10 U/ml heparin, was placed in the femoral artery. After the scro-
tum was incised, the cremaster muscle was carefully exteriorized 
onto an intravital microscopy tray so that it could be monitored 
without detaching it from the body. The muscle preparation was 
superfused with thermo-controlled (37 °C) and aerated (95% N2, Platelets from hESCs are functional in vitro and in mice
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5% CO2) bicarbonate-buffered saline throughout the experiment.
The cremaster muscle arteriolar wall was injured by laser ab-
lation using a Micropoint Laser System (Photonics Instruments, 
South Windsor, CT, USA) as described previously [29]. The de-
veloping mouse platelet thrombus was monitored by infusion of 
Dylight 649 (red)-labeled anti-mouse CD42 (Emfret Analytics, 
0.05 µg/g body weight). One or two pulses ablated an inside ves-
sel wall to stimulate platelet thrombus formation. To determine if 
they could incorporate into the developing mouse platelet throm-
bus, human blood platelets or hESC-PLTs, labeled with calcein 
AM, (green, Invitrogen; 50-100 µl per 5-10 × 10
5 platelets) were 
infused through a femoral artery cannulus while the mouse plate-
let thrombus (red) was growing. Multiple thrombi were studied 
in one mouse, with each new ablation being made upstream of 
the earlier one to avoid any previous thrombus contribution to 
the newly forming one. Labeled human platelets, which had been 
previously infused into a mouse were allowed to completely clear 
the microcirculation before a new vascular ablation was made. To 
determine whether their incorporation was dependent on αIIbβ3 
integrin signaling, human blood platelets, or hESC-PLTs were pre-
treated with ReoPro (20 µg for 2 × 10
6 human platelets in 200 µl, 
Centocor) before infusion. ReoPro is a Fab fragment of a human-
murine chimeric monoclonal antibody that specifically binds to 
αIIbβ3 integrin on human platelets and inhibits its function [30]. 
In general, two to three ablation-induced thrombi were allowed to 
form in each mouse to establish human platelet incorporation pa-
rameters without ReoPro. Then, another two to three thrombi were 
generated to examine incorporation of the ReoPro-treated human 
platelets. Human blood platelets and hESC-PLTs were studied in 
different mice. Microvessel data were obtained using an Olympus 
BX61WI microscope with a 60× objective. Digital images were 
captured with a high-speed digital camera (Hamamatsu C9300) 
through an intensifier (Video Scope International, Dulles, VA, 
USA). Fluorescence images were analyzed using Slidebook v5.0 
(Intelligent Imaging Innovations, Denvor, CO, USA). Fluorescence 
images were captured at exposure times of 10-100 milliseconds 
and bright field images were captured with exposure times of 20 
milliseconds. Data were collected for 3 min following vessel wall 
injury. To simplify the image analysis, the dynamic range of the 
intensity of each pseudocolor was binarized. The number of hu-
man platelets circulating in the microvessel and incorporated into 
the developing mouse platelet thrombus at the site of vessel injury 
was counted over 3-4 min after vascular injury. The kinetics of 
mouse platelet thrombus formation were analyzed by determining 
median fluorescence intensity values of anti-CD42 antibody over 
time in approximately five to eight thrombi in three mice [29]. Tmax 
and 1/2 Tmax were defined as the time points at which the mouse 
platelet thrombus had reached its maximum and 1/2 maximum 
size, respectively. 
Statistical analysis
Data were statistically analyzed by Student’s t-test for compari-
son of two groups using GraphPad Prism (GraphPad Software). 
Differences were considered significant at P < 0.05.
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